GPR3 protein's role in different brain cells in Alzheimer's
Cell-type-specific functions of GPR3 in Alzheimer’s disease
Testing whether changing how the GPR3 protein signals in brain cells can lower amyloid buildup and help people with Alzheimer's disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11243494 on NIH RePORTER |
What this research studies
Researchers use genetically modified mice that alter GPR3 signaling to see how different brain cells (microglia, astrocytes, oligodendrocytes) respond to amyloid and tau pathology. They compare animals with normal, missing, or biased GPR3 signaling to measure amyloid levels, plaque burden, glial activation, and cognitive behaviors. The team focuses on cell-type-specific effects to identify signaling pathways that could be targeted by drugs that favor beneficial G protein signaling over β-arrestin pathways. Findings aim to inform development of GPR3-directed therapies that mimic the protective effects seen in mice.
Who could benefit from this research
Good fit: People with early-stage Alzheimer's disease or mild cognitive impairment due to Alzheimer pathology would be the most likely candidates for future GPR3-targeted treatments.
Not a fit: People with non‑Alzheimer dementias or very advanced Alzheimer's disease are less likely to benefit from GPR3-directed approaches.
Why it matters
Potential benefit: If successful, this work could point to new drugs that reduce amyloid and protect thinking by targeting GPR3 signaling in specific brain cells.
How similar studies have performed: Preclinical work from this team showed that biased GPR3 signaling in mice reduced amyloid and preserved cognition, but this approach has not yet been tested in people.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Thathiah, Amantha — University of Pittsburgh at Pittsburgh
- Study coordinator: Thathiah, Amantha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.